Table 3.
CMR Findings and NT-proBNP Levels at 6 Months Post-STEMI Stratified According to Higher and Lower T1 in the Noninfarcted Myocardium on the Acute Scan
| CMR Findings at 6 Months | Patients With Follow-Up CMR (n = 152) | Acute Noninfarct T1 |
||
|---|---|---|---|---|
| High (>1,250 ms) (47% of Cohort) | Normal (≤1,250 ms) (53% of cohort) | P Value | ||
| LVEDVI, mL/m2 | 84 ± 19a | 86 ± 20 | 81 ± 18 | 0.115 |
| LVESVI, mL/m2 | 40 ± 15a | 44 ± 16 | 38 ± 14 | 0.015 |
| LVEF, % | 53 ± 9a | 51 ± 8 | 55 ± 9 | 0.002 |
| RVEDVI, mL/m2 | 71 ± 14a | 70 ± 14 | 71 ± 14 | 0.541 |
| RVESVI, mL/m2 | 29 ± 9a | 29 ± 8 | 29 ± 9 | 0.649 |
| RVEF, % | 60 ± 7a | 60 ± 7 | 60 ± 6 | 0.899 |
| Final infarct size, % | 16 (8-24)a | 19 (10-28) | 13 (8-25) | 0.005 |
| Myocardial salvage index, % | 61 (45-76) | 58 (42-72) | 64 (46-78) | 0.258 |
| Change in LVEDV vs baseline, % | 1.6 (−8.1 to 11.2) | 2.8 (−8.3 to 14) | 0.9 (−5.4 to 4.4) | 0.267 |
| Significant adverse remodeling, frequency in % | 14 | 9 | 15 | 0.226 |
| Absolute change in LVEF | 5 (0-10) | 7 (2-12) | 3 (−1 to 8) | 0.011 |
| Blood test findings at 6 mo | ||||
| NT-proBNP, pg/mL | 198 (88-398) | 290 (103-523) | 170 (61-312) | 0.008 |
Values are mean ± SD, median (IQR), or %.
a
P < 0.001 when compared with acute CMR scan findings in Table 2. Significant adverse remodeling is defined as ≥20% increase in LVEDV. Values in bold indicate a value of P < 0.05.